<HashMap><database>biostudies-literature</database><scores/><additional><submitter>He Z</submitter><funding>the fund of Scholar Research of Kagoshima University</funding><pagination>e2108</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11680972</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>51(1)</volume><pubmed_abstract>The mitogen-activated protein kinase kinase 4 (MKK4), a member of the MAP kinase kinase family, directly phosphorylates and activates the c-Jun NH2-terminal kinases (JNK), in response to proinflammatory cytokines and cellular stresses. Regulation of the MKK4 activity is considered to be a novel approach for the prevention and treatment of inflammation. The aim of this study was to identify whether fisetin, a potential anti-inflammatory compound, targets MKK4-JNK cascade to inhibit lipopolysaccharide (LPS)-stimulated inflammatory response. RAW264 macrophage pretreated with fisetin following LPS stimulation was used as a cell model to investigate the transactivation and expression of related-inflammatory genes by transient transfection assay, electrophoretic mobility shift assay (EMSA), or e</pubmed_abstract><journal>BioFactors (Oxford, England)</journal><pubmed_title>Fisetin is a selective adenosine triphosphate-competitive inhibitor for mitogen-activated protein kinase kinase 4 to inhibit lipopolysaccharide-stimulated inflammation.</pubmed_title><pmcid>PMC11680972</pmcid><funding_grant_id>70030117</funding_grant_id><pubmed_authors>Uto T</pubmed_authors><pubmed_authors>Pan X</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>He Z</pubmed_authors><pubmed_authors>Kumamoto T</pubmed_authors><pubmed_authors>Xie K</pubmed_authors><pubmed_authors>Tanigawa S</pubmed_authors><pubmed_authors>Wu S</pubmed_authors><pubmed_authors>Hou DX</pubmed_authors><pubmed_authors>Sakao K</pubmed_authors><pubmed_authors>Komatsu M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Fisetin is a selective adenosine triphosphate-competitive inhibitor for mitogen-activated protein kinase kinase 4 to inhibit lipopolysaccharide-stimulated inflammation.</name><description>The mitogen-activated protein kinase kinase 4 (MKK4), a member of the MAP kinase kinase family, directly phosphorylates and activates the c-Jun NH2-terminal kinases (JNK), in response to proinflammatory cytokines and cellular stresses. Regulation of the MKK4 activity is considered to be a novel approach for the prevention and treatment of inflammation. The aim of this study was to identify whether fisetin, a potential anti-inflammatory compound, targets MKK4-JNK cascade to inhibit lipopolysaccharide (LPS)-stimulated inflammatory response. RAW264 macrophage pretreated with fisetin following LPS stimulation was used as a cell model to investigate the transactivation and expression of related-inflammatory genes by transient transfection assay, electrophoretic mobility shift assay (EMSA), or e</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jan-Feb</publication><modification>2026-04-13T03:23:09.824Z</modification><creation>2025-04-04T02:48:36.665Z</creation></dates><accession>S-EPMC11680972</accession><cross_references><pubmed>39087587</pubmed><doi>10.1002/biof.2108</doi></cross_references></HashMap>